Q4 EPS Estimates for Biomea Fusion Boosted by HC Wainwright

Key Points

• HC Wainwright has increased its Q4 2025 EPS estimates for Biomea Fusion, projecting a loss of ($0.20) per share, an improvement from the previous estimate of ($0.23).
• Multiple analysts have rated Biomea Fusion's stock, with one strong buy, six buy ratings, one hold, and one sell, resulting in a consensus rating of "Moderate Buy" with an average target price of $9.50.
• Biomea Fusion's stock has seen a 1.2% decline, with a current price of $1.65, compared to its 52-week low of $1.29 and a high of $12.85.

Biomea Fusion, Inc. (NASDAQ:BMEA - Free Report) - Equities researchers at HC Wainwright boosted their Q4 2025 earnings per share (EPS) estimates for Biomea Fusion in a report issued on Tuesday, October 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.20) for the quarter, up from their previous forecast of ($0.23). The consensus estimate for Biomea Fusion's current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion's FY2026 earnings at ($1.21) EPS, FY2027 earnings at ($1.24) EPS and FY2028 earnings at ($1.44) EPS.

Other analysts have also recently issued research reports about the company. Jefferies Financial Group initiated coverage on Biomea Fusion in a research report on Thursday, August 28th. They set a "buy" rating and a $5.00 target price for the company. Oppenheimer restated an "outperform" rating on shares of Biomea Fusion in a report on Tuesday, August 5th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Biomea Fusion in a report on Wednesday, October 8th. Scotiabank dropped their target price on Biomea Fusion from $30.00 to $10.00 and set a "sector outperform" rating for the company in a report on Wednesday, August 6th. Finally, Citigroup dropped their target price on Biomea Fusion from $9.00 to $7.00 and set a "buy" rating for the company in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $9.50.

Biomea Fusion Stock Down 1.2%

NASDAQ BMEA opened at $1.65 on Thursday. The stock's 50-day moving average price is $1.88 and its 200-day moving average price is $1.88. Biomea Fusion has a 52 week low of $1.29 and a 52 week high of $12.85. The company has a market capitalization of $98.19 million, a P/E ratio of -0.54 and a beta of -0.12.

Biomea Fusion (NASDAQ:BMEA - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08.

Institutional Investors Weigh In On Biomea Fusion

A number of institutional investors and hedge funds have recently bought and sold shares of BMEA. Engineers Gate Manager LP bought a new stake in Biomea Fusion during the 2nd quarter valued at $26,000. CWM LLC raised its position in shares of Biomea Fusion by 8,058.5% in the 1st quarter. CWM LLC now owns 16,888 shares of the company's stock worth $36,000 after acquiring an additional 16,681 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Biomea Fusion in the 1st quarter worth $37,000. Marex Group plc bought a new position in shares of Biomea Fusion in the 2nd quarter worth $81,000. Finally, Exchange Traded Concepts LLC raised its position in shares of Biomea Fusion by 140.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 50,550 shares of the company's stock worth $108,000 after acquiring an additional 29,565 shares in the last quarter. 96.72% of the stock is owned by institutional investors.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.